Article 441: Top 20 Pharma Flock to China, Set Up CRUs (Part II of a Two-part Series)

• China continues its rapid market growth at about 18% annually, and the country's market size should reach about $14 billion this year. With a population of 1.3 billion, enthusiastic investigators trained in the West and accredited by the government in GCP and a highly centralized healthcare system that gives access to millions of treatment-naïve patients per day, major pharma companies are making a serious commitment in China by setting up clinical research units.

Article 442: 2005: The Year of Surprising Data

• CenterWatch reviews a turbulent year in the clinical trials industry, which was once again buffeted by negative press and numerous calls for more transparency in clinical trials results reporting. However, CenterWatch data revealed that behind some of these mainstream misperceptions of the industry, there were some encouraging emerging trends.

Article 443: European Regulation Targets Drugs for Children

• The European Commission is poised to introduce legislation governing medicines given to children.

Article 444: Eye on: Alzheimer's Disease

• Alzheimer's disease (AD) is the leading cause of age-associated dementia. CenterWatch has identified a pipeline of 30 drugs in development for AD.